12. August 2025 - RoTecPSMA® Approved in Switzerland – Expanding Access to Advanced Prostate Cancer Diagnostics. We are delighted to announce that RoTecPSMA® has received marketing authorization in Switzerland, marking another important milestone in the European rollout of this innovative diagnostic solution. This approval, achieved in close collaboration with our trusted partner and marketing authorization holder medeo AG, paves the way for Swiss patients to benefit from our PSMA SPECT tracer.

18. Juli 2025 - Team ROTOP is back from SNMMI 2025 in New Orleans and feels energized by the global momentum in radiopharmaceuticals. Team ROTOP - Jens Junker, Felix Roschke, Thomas Gottlieb and Tanmaya Joshi - just returned from SNMMI 2025 in New Orleans. This year, the event brought together nearly 8,000 professionals from across the nuclear medicine and radiopharmaceutical world.